Albeit still limited in efficacy, angiogenesis - inhibiting drugs have become part of
standard tumor therapy supporting the efficacy of established chemotherapies.
Not exact matches
The Moores Cancer Center's Molecular
Tumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard thera
Tumor Board brought together medical, surgical and radiation
therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of
tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard thera
tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted
standard therapies.
No targeted
therapy has been approved for noninflammatory and inflammatory triple - negative breast cancer
tumors, and the
standard of
therapy for these
tumors is a combination of conventional cytotoxic chemotherapeutic agents.
The Phase I clinical trial of OMP - 54F28 (FZD8 - Fc) is an open - label dose escalation study in patients with advanced solid
tumors for which there was no remaining
standard curative
therapy.
The finding, reported by a Stand Up to Cancer - Prostate Cancer Foundation Dream Team in the May 21 edition of the journal Cell, is based on an analysis of
tumor samples from 150 men with metastatic prostate cancer that no longer responded to
standard hormone - blocking
therapy.
A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to
standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms
tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen
Research on metastatic colorectal cancer and sarcoma, however, suggests a potential benefit from adding local
therapy — treatment directed specifically at the
tumor cells — to the
standard approach of systemic
therapy.
EGFR tyrosine kinase inhibitor (TKI)
therapy is approved for EGFR activating mutation positive patients with advanced NSCLC, but the
standard for determining mutation status is with DNA derived directly from
tumor tissue, which can be limited or not available.
Loeb points out that much of the concern over cancer risk is that, as part of
standard therapy for advanced prostate cancer,
tumor growth is decreased by drugs that drastically reduce rather than increase male hormones.
Two case studies provide an important potential new avenue for treatment of these types of
tumors, which are resistant to traditional radiation
therapies and difficult to manage even with surgery, the current
standard of care.
Avastin is a drug that is known to shrink brain
tumors and is a
standard therapy for recurrent GBM.
The current
standard of care for a newly diagnosed, high - grade glioma includes surgically removing as much of the
tumor as possible, followed by radiation
therapy and chemotherapy.
Surgery — the
standard therapy for treating hepatoblastoma and other liver
tumors is surgery to remove the
tumor.
Even with the
standard - of - care
therapy of amputation and chemotherapy, the prognosis is poor, with most dogs dying due to
tumor spread (metastasis) within one year, and less than 20 % surviving to 2 years following diagnosis.